LSD Therapy Reduces Anxiety in Major Clinical Trial

Definium Therapeutics announced Wednesday that a single dose of its LSD therapy pill helped patients with generalized anxiety disorder in a late-stage clinical trial. The results bring new hope to millions living with persistent anxiety.

The Phase 3 study tested 214 patients who received either DT120, a pharmaceutically optimized LSD pill, or a placebo. Patients who took the LSD treatment showed significant improvement compared to those who received the inactive pill.

This marks Definium's second major win in recent months. In June, the company reported success using the same therapy to treat major depression in another large trial.

Generalized anxiety disorder affects roughly 6.8 million American adults, causing persistent worry that interferes with daily life. Current treatments include therapy and medications like SSRIs, but many patients struggle to find relief or experience unwanted side effects.

The Ripple Effect

The promising results add momentum to the growing field of psychedelic medicine. For decades, substances like LSD and psilocybin faced legal and social barriers that prevented scientific research, despite anecdotal reports of mental health benefits.

Recent years have seen a shift. Researchers at major universities now study psychedelics for conditions ranging from PTSD to addiction. Several companies are working to bring these therapies through rigorous FDA trials.

Definium's approach involves creating a standardized, pharmaceutical-grade version of LSD that can be safely manufactured and precisely dosed. This differs from recreational use and allows doctors to prescribe consistent treatments.

The company hasn't yet published full trial data, which will reveal exactly how much the therapy helped and what side effects occurred. Two successful Phase 3 trials typically precede FDA approval applications.

If approved, the treatment would join a small but growing list of psychedelic-based medicines gaining mainstream acceptance. MDMA therapy for PTSD and psilocybin for depression are also advancing through clinical trials.

For people with anxiety who haven't found relief from existing options, today's news offers a glimpse of new possibilities on the horizon.